{
  "FullStudy":{
    "Rank":217893,
    "Study":{
      "ProtocolSection":{
        "IdentificationModule":{
          "NCTId":"NCT01515462",
          "OrgStudyIdInfo":{
            "OrgStudyId":"201228"
          },
          "SecondaryIdInfoList":{
            "SecondaryIdInfo":[
              {
                "SecondaryId":"2009-017346-32",
                "SecondaryIdType":"EudraCT Number"
              }
            ]
          },
          "Organization":{
            "OrgFullName":"Orchard Therapeutics",
            "OrgClass":"INDUSTRY"
          },
          "BriefTitle":"Gene Therapy for Wiskott-Aldrich Syndrome",
          "OfficialTitle":"A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome",
          "Acronym":"TIGET-WAS"
        },
        "StatusModule":{
          "StatusVerifiedDate":"January 2020",
          "OverallStatus":"Active, not recruiting",
          "ExpandedAccessInfo":{
            "HasExpandedAccess":"No"
          },
          "StartDateStruct":{
            "StartDate":"April 20, 2010",
            "StartDateType":"Actual"
          },
          "PrimaryCompletionDateStruct":{
            "PrimaryCompletionDate":"October 3, 2018",
            "PrimaryCompletionDateType":"Actual"
          },
          "CompletionDateStruct":{
            "CompletionDate":"September 11, 2025",
            "CompletionDateType":"Anticipated"
          },
          "StudyFirstSubmitDate":"December 23, 2011",
          "StudyFirstSubmitQCDate":"January 18, 2012",
          "StudyFirstPostDateStruct":{
            "StudyFirstPostDate":"January 24, 2012",
            "StudyFirstPostDateType":"Estimate"
          },
          "LastUpdateSubmitDate":"January 6, 2020",
          "LastUpdatePostDateStruct":{
            "LastUpdatePostDate":"January 7, 2020",
            "LastUpdatePostDateType":"Actual"
          }
        },
        "SponsorCollaboratorsModule":{
          "ResponsibleParty":{
            "ResponsiblePartyType":"Sponsor"
          },
          "LeadSponsor":{
            "LeadSponsorName":"Orchard Therapeutics",
            "LeadSponsorClass":"INDUSTRY"
          },
          "CollaboratorList":{
            "Collaborator":[
              {
                "CollaboratorName":"Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)",
                "CollaboratorClass":"UNKNOWN"
              }
            ]
          }
        },
        "OversightModule":{
          "OversightHasDMC":"No",
          "IsFDARegulatedDrug":"No",
          "IsFDARegulatedDevice":"No"
        },
        "DescriptionModule":{
          "BriefSummary":"This is phase I/II protocol to evaluate the safety and efficacy of WAS gene transfer into hematopoietic stem/progenitor cells for the treatment of Wiskott Aldrich Syndrome.",
          "DetailedDescription":"Wiskott-Aldrich Syndrome (WAS) is an X-linked primary immunodeficiency caused by mutations in the WAS gene which encodes the WAS protein (WASP), a cytoskeletal regulator which is expressed exclusively in hematopoietic cells."
        },
        "ConditionsModule":{
          "ConditionList":{
            "Condition":[
              "Wiskott-Aldrich Syndrome (WAS)"
            ]
          },
          "KeywordList":{
            "Keyword":[
              "Lentiviral vector",
              "Gene therapy",
              "Wiskott-Aldrich Syndrome",
              "OTL-103",
              "Previously GSK2696275"
            ]
          }
        },
        "DesignModule":{
          "StudyType":"Interventional",
          "PhaseList":{
            "Phase":[
              "Phase 1",
              "Phase 2"
            ]
          },
          "DesignInfo":{
            "DesignInterventionModel":"Single Group Assignment",
            "DesignInterventionModelDescription":"This will be a single-arm study. All subjects will receive OTL-103 gene therapy and will be followed up for 8 years post gene therapy",
            "DesignPrimaryPurpose":"Treatment",
            "DesignMaskingInfo":{
              "DesignMasking":"None (Open Label)"
            }
          },
          "EnrollmentInfo":{
            "EnrollmentCount":"8",
            "EnrollmentType":"Actual"
          }
        },
        "ArmsInterventionsModule":{
          "ArmGroupList":{
            "ArmGroup":[
              {
                "ArmGroupLabel":"OTL-103 gene therapy",
                "ArmGroupType":"Experimental",
                "ArmGroupDescription":"Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included",
                "ArmGroupInterventionList":{
                  "ArmGroupInterventionName":[
                    "Genetic: OTL-103"
                  ]
                }
              }
            ]
          },
          "InterventionList":{
            "Intervention":[
              {
                "InterventionType":"Genetic",
                "InterventionName":"OTL-103",
                "InterventionDescription":"OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein",
                "InterventionArmGroupLabelList":{
                  "InterventionArmGroupLabel":[
                    "OTL-103 gene therapy"
                  ]
                },
                "InterventionOtherNameList":{
                  "InterventionOtherName":[
                    "Previously GSK2696275"
                  ]
                }
              }
            ]
          }
        },
        "OutcomesModule":{
          "PrimaryOutcomeList":{
            "PrimaryOutcome":[
              {
                "PrimaryOutcomeMeasure":"Conditioning regimen-related safety",
                "PrimaryOutcomeDescription":"Absence of engraftment failure or prolonged aplasia (<500/ul ANC with no evidence of bone marrow recovery) and surveillance of non haematological regimen related toxicity (for clinical features NCI >2, for metabolic/laboratory NCI >3)",
                "PrimaryOutcomeTimeFrame":"Two months after gene therapy"
              },{
                "PrimaryOutcomeMeasure":"Safety of lentivirus gene transfer into HSC",
                "PrimaryOutcomeDescription":"Short-term safety and tolerability of lentiviral-transduced cell infusion-long-term safety of lentiviral-transduced cell infusion (absence of Replication Competent Lentivirus (RCL) and abnormal clonal proliferation).",
                "PrimaryOutcomeTimeFrame":"3 years"
              },{
                "PrimaryOutcomeMeasure":"Sustained engraftment of genetically corrected haematopoietic stem cells in peripheral blood and/or in bone marrow",
                "PrimaryOutcomeDescription":"≥ 0.04 Vector copy number (VCN)/cell in bone marrow CD34+ or ≥0.1 VCN/cell in peripheral blood T lymphocytes",
                "PrimaryOutcomeTimeFrame":"1 year"
              },{
                "PrimaryOutcomeMeasure":"Expression of vector-derived WASP",
                "PrimaryOutcomeDescription":"Detection of vector-derived WASP expression by FACS analyses and/or Western Blot",
                "PrimaryOutcomeTimeFrame":"1 year"
              },{
                "PrimaryOutcomeMeasure":"Improved T-cell functions",
                "PrimaryOutcomeDescription":"Improvement in in vitro T cell proliferation and/or IL-2 secretion upon stimulation with anti-CD3i as compared to pre-gene therapy values.",
                "PrimaryOutcomeTimeFrame":"3 years"
              },{
                "PrimaryOutcomeMeasure":"Antigen-specific responses to vaccination",
                "PrimaryOutcomeDescription":"Ability to mount a humoral response to nominal antigens including antibodies to T cell dependent antigens (Tetanus Toxoid) and unconjugated polysaccharide antigens (Peumococcus, Meningococcus), measured after vaccination (foreseen >1 year after gene therapy). Positive cellular response to Tetanus Toxoid after vaccination measured by in vitro proliferative response >1 year after gene therapy.",
                "PrimaryOutcomeTimeFrame":">1year"
              },{
                "PrimaryOutcomeMeasure":"Improved platelet count and MPV normalization",
                "PrimaryOutcomeDescription":"Sustained increase in platelet count compared to baseline, analyzing the individual longitudinal profile",
                "PrimaryOutcomeTimeFrame":"3 years"
              },{
                "PrimaryOutcomeMeasure":"Overall survival",
                "PrimaryOutcomeDescription":"Number of patients alive all over the trial",
                "PrimaryOutcomeTimeFrame":"3 years"
              }
            ]
          },
          "SecondaryOutcomeList":{
            "SecondaryOutcome":[
              {
                "SecondaryOutcomeMeasure":"Lack of immune response to transgene",
                "SecondaryOutcomeDescription":"Immunoblot analysis",
                "SecondaryOutcomeTimeFrame":"3 years"
              },{
                "SecondaryOutcomeMeasure":"Reduced frequency of severe infections",
                "SecondaryOutcomeDescription":"Decrease in number of severe infections as evaluated in the second and third year after the treatment by clinical history, complete physical examinations, hematological and microbiological tests.",
                "SecondaryOutcomeTimeFrame":"3 years"
              },{
                "SecondaryOutcomeMeasure":"Reduced bruising and bleeding episodes",
                "SecondaryOutcomeDescription":"Reduction in bruising and/or bleeding manifestations when present, as assessed by clinical monitoring, compared to clinical history",
                "SecondaryOutcomeTimeFrame":"3 years"
              },{
                "SecondaryOutcomeMeasure":"Reduced autoimmunity phenomena and eczema",
                "SecondaryOutcomeDescription":"Reduction in laboratory markers (number and titer of antibody when available) and/or clinical manifestations of autoimmunity, as evaluated by organ-specific and systemic autoantibodies, imaging and clinical follow-up, compared to clinical history. Reduction in eczema as evaluated by clinical score",
                "SecondaryOutcomeTimeFrame":"3 years"
              },{
                "SecondaryOutcomeMeasure":"Improved quality of life",
                "SecondaryOutcomeDescription":"Improved quality of life, measured after the first year of treatment by reduced hospitalization, reduced requirement of drugs, school attendance, social activities.",
                "SecondaryOutcomeTimeFrame":"3 year"
              },{
                "SecondaryOutcomeMeasure":"Multilineage engraftment of genetically corrected cells",
                "SecondaryOutcomeDescription":"≥0.04 VCN/cell on all the available peripheral blood and/or bone marrow cell subpopulations (BM subpopulations: GlyA+, CD15+, CD61+, CD3+, CD19+, CD56+; PB subpopulations: CD15+, CD19+, CD56+)",
                "SecondaryOutcomeTimeFrame":"3 years"
              },{
                "SecondaryOutcomeMeasure":"Overall safety of the treatment",
                "SecondaryOutcomeDescription":"Recording of AE, AR, SAE/SAR, UAR, SUSAR",
                "SecondaryOutcomeTimeFrame":"8 years"
              }
            ]
          }
        },
        "EligibilityModule":{
          "EligibilityCriteria":"Inclusion Criteria:\n\nDiagnosis of WAS defined by genetic mutation and at least one of the following criteria:\n\nSevere WAS mutation\nAbsence of WASP expression\nSevere clinical score (Zhu clinical score ≥ 3\nNo HLA-identical sibling donor\n\nNegative search for a matched unrelated donor (10/10) or an adequate unrelated cord blood donor (5-6/6) within 4-6 months\n\nPatients of > 5 years of age who are not candidate to unrelated allogeneic transplant based on clinical conditions.\nParental/guardian/patient signed informed consent.\n\nExclusion Criteria:\n\nPatients positive for HIV-infection.\nPatients affected by neoplasia.\nPatients with cytogenetic alterations typical of MDS/AML.\nPatients with end-organ functions or any other severe disease which, in the judgement of the investigator, would make the patient inappropriate for entry into this study.\nPatients who underwent an allogeneic haematopoietic stem cell transplantation in the previous 6 months.\nPatients who underwent an allogeneic haematopoietic stem cell transplantation with evidence of residual cells of donor origin.",
          "HealthyVolunteers":"No",
          "Gender":"All",
          "StdAgeList":{
            "StdAge":[
              "Child",
              "Adult",
              "Older Adult"
            ]
          }
        },
        "ContactsLocationsModule":{
          "OverallOfficialList":{
            "OverallOfficial":[
              {
                "OverallOfficialName":"Orchard Clinical Trials",
                "OverallOfficialAffiliation":"Orchard Therapeutics",
                "OverallOfficialRole":"Study Director"
              }
            ]
          },
          "LocationList":{
            "Location":[
              {
                "LocationFacility":"Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)",
                "LocationCity":"Milan",
                "LocationZip":"20132",
                "LocationCountry":"Italy"
              }
            ]
          }
        },
        "ReferencesModule":{
          "ReferenceList":{
            "Reference":[
              {
                "ReferencePMID":"23845947",
                "ReferenceType":"background",
                "ReferenceCitation":"Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee PP, Orange JS, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013 Aug 23;341(6148):1233151. doi: 10.1126/science.1233151. Epub 2013 Jul 11."
              },{
                "ReferencePMID":"19179314",
                "ReferenceType":"background",
                "ReferenceCitation":"Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009 Jan 29;360(5):447-58. doi: 10.1056/NEJMoa0805817."
              },{
                "ReferencePMID":"20008254",
                "ReferenceType":"background",
                "ReferenceCitation":"Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program. 2009:682-9. doi: 10.1182/asheducation-2009.1.682. Review."
              },{
                "ReferencePMID":"19351959",
                "ReferenceType":"background",
                "ReferenceCitation":"Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009 Jun 18;113(25):6288-95. doi: 10.1182/blood-2008-12-115253. Epub 2009 Apr 7. Review."
              },{
                "ReferencePMID":"17078381",
                "ReferenceType":"background",
                "ReferenceCitation":"Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct;8(5):390-5. Review."
              },{
                "ReferencePMID":"15308573",
                "ReferenceType":"background",
                "ReferenceCitation":"Burns S, Cory GO, Vainchenker W, Thrasher AJ. Mechanisms of WASp-mediated hematologic and immunologic disease. Blood. 2004 Dec 1;104(12):3454-62. Epub 2004 Aug 12. Review."
              },{
                "ReferencePMID":"17051251",
                "ReferenceType":"background",
                "ReferenceCitation":"Charrier S, Dupré L, Scaramuzza S, Jeanson-Leh L, Blundell MP, Danos O, Cattaneo F, Aiuti A, Eckenberg R, Thrasher AJ, Roncarolo MG, Galy A. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 2007 Mar;14(5):415-28. Epub 2006 Oct 19."
              },{
                "ReferencePMID":"15509508",
                "ReferenceType":"background",
                "ReferenceCitation":"Dupré L, Trifari S, Follenzi A, Marangoni F, Lain de Lera T, Bernad A, Martino S, Tsuchiya S, Bordignon C, Naldini L, Aiuti A, Roncarolo MG. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther. 2004 Nov;10(5):903-15."
              },{
                "ReferencePMID":"11812281",
                "ReferenceType":"background",
                "ReferenceCitation":"Follenzi A, Sabatino G, Lombardo A, Boccaccio C, Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther. 2002 Jan 20;13(2):243-60."
              },{
                "ReferencePMID":"18194074",
                "ReferenceType":"background",
                "ReferenceCitation":"Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther. 2008 Feb;8(2):181-90. doi: 10.1517/14712598.8.2.181 . Review."
              },{
                "ReferencePMID":"19259069",
                "ReferenceType":"background",
                "ReferenceCitation":"Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S, Panaroni C, Ponzoni M, Sanvito F, Doglioni C, Liabeuf M, Gjata B, Montus M, Siminovitch K, Aiuti A, Naldini L, Dupré L, Roncarolo MG, Galy A, Villa A. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther. 2009 Jun;17(6):1073-82. doi: 10.1038/mt.2009.31. Epub 2009 Mar 3. Erratum in: Mol Ther. 2009 Jul;17(7):1300."
              },{
                "ReferencePMID":"7795648",
                "ReferenceType":"background",
                "ReferenceCitation":"Villa A, Notarangelo L, Macchi P, Mantuano E, Cavagni G, Brugnoni D, Strina D, Patrosso MC, Ramenghi U, Sacco MG, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995 Apr;9(4):414-7."
              },{
                "ReferencePMID":"30981783",
                "ReferenceType":"derived",
                "ReferenceCitation":"Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, Migliavacca M, Bernardo ME, Calbi V, Assanelli AA, Facchini M, Fossati C, Albertazzi E, Scaramuzza S, Brigida I, Scala S, Basso-Ricci L, Pajno R, Casiraghi M, Canarutto D, Salerio FA, Albert MH, Bartoli A, Wolf HM, Fiori R, Silvani P, Gattillo S, Villa A, Biasco L, Dott C, Culme-Seymour EJ, van Rossem K, Atkinson G, Valsecchi MG, Roncarolo MG, Ciceri F, Naldini L, Aiuti A. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematol. 2019 May;6(5):e239-e253. doi: 10.1016/S2352-3026(19)30021-3. Epub 2019 Apr 10."
              }
            ]
          }
        }
      },
      "DerivedSection":{
        "MiscInfoModule":{
          "VersionHolder":"April 22, 2020"
        },
        "ConditionBrowseModule":{
          "ConditionMeshList":{
            "ConditionMesh":[
              {
                "ConditionMeshId":"D000014923",
                "ConditionMeshTerm":"Wiskott-Aldrich Syndrome"
              },{
                "ConditionMeshId":"D000013577",
                "ConditionMeshTerm":"Syndrome"
              }
            ]
          },
          "ConditionAncestorList":{
            "ConditionAncestor":[
              {
                "ConditionAncestorId":"D000004194",
                "ConditionAncestorTerm":"Disease"
              },{
                "ConditionAncestorId":"D000010335",
                "ConditionAncestorTerm":"Pathologic Processes"
              },{
                "ConditionAncestorId":"D000025861",
                "ConditionAncestorTerm":"Blood Coagulation Disorders, Inherited"
              },{
                "ConditionAncestorId":"D000001778",
                "ConditionAncestorTerm":"Blood Coagulation Disorders"
              },{
                "ConditionAncestorId":"D000006402",
                "ConditionAncestorTerm":"Hematologic Diseases"
              },{
                "ConditionAncestorId":"D000006474",
                "ConditionAncestorTerm":"Hemorrhagic Disorders"
              },{
                "ConditionAncestorId":"D000008231",
                "ConditionAncestorTerm":"Lymphopenia"
              },{
                "ConditionAncestorId":"D000007970",
                "ConditionAncestorTerm":"Leukopenia"
              },{
                "ConditionAncestorId":"D000007960",
                "ConditionAncestorTerm":"Leukocyte Disorders"
              },{
                "ConditionAncestorId":"D000030342",
                "ConditionAncestorTerm":"Genetic Diseases, Inborn"
              },{
                "ConditionAncestorId":"D000040181",
                "ConditionAncestorTerm":"Genetic Diseases, X-Linked"
              },{
                "ConditionAncestorId":"D000007153",
                "ConditionAncestorTerm":"Immunologic Deficiency Syndromes"
              },{
                "ConditionAncestorId":"D000007154",
                "ConditionAncestorTerm":"Immune System Diseases"
              }
            ]
          },
          "ConditionBrowseLeafList":{
            "ConditionBrowseLeaf":[
              {
                "ConditionBrowseLeafId":"M14938",
                "ConditionBrowseLeafName":"Syndrome",
                "ConditionBrowseLeafAsFound":"Syndrome",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"M16245",
                "ConditionBrowseLeafName":"Wiskott-Aldrich Syndrome",
                "ConditionBrowseLeafAsFound":"Wiskott-Aldrich Syndrome",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"M20561",
                "ConditionBrowseLeafName":"Hemostatic Disorders",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M3641",
                "ConditionBrowseLeafName":"Blood Coagulation Disorders",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M21679",
                "ConditionBrowseLeafName":"Blood Coagulation Disorders, Inherited",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M8073",
                "ConditionBrowseLeafName":"Hematologic Diseases",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M8143",
                "ConditionBrowseLeafName":"Hemorrhagic Disorders",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M9807",
                "ConditionBrowseLeafName":"Lymphopenia",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M9556",
                "ConditionBrowseLeafName":"Leukopenia",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M9546",
                "ConditionBrowseLeafName":"Leukocyte Disorders",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M22270",
                "ConditionBrowseLeafName":"Genetic Diseases, Inborn",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M23464",
                "ConditionBrowseLeafName":"Genetic Diseases, X-Linked",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M8782",
                "ConditionBrowseLeafName":"Immunologic Deficiency Syndromes",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M8783",
                "ConditionBrowseLeafName":"Immune System Diseases",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"T5962",
                "ConditionBrowseLeafName":"Wiskott Aldrich Syndrome",
                "ConditionBrowseLeafAsFound":"Wiskott-Aldrich Syndrome",
                "ConditionBrowseLeafRelevance":"high"
              }
            ]
          },
          "ConditionBrowseBranchList":{
            "ConditionBrowseBranch":[
              {
                "ConditionBrowseBranchAbbrev":"BC23",
                "ConditionBrowseBranchName":"Symptoms and General Pathology"
              },{
                "ConditionBrowseBranchAbbrev":"All",
                "ConditionBrowseBranchName":"All Conditions"
              },{
                "ConditionBrowseBranchAbbrev":"BC15",
                "ConditionBrowseBranchName":"Blood and Lymph Conditions"
              },{
                "ConditionBrowseBranchAbbrev":"BC16",
                "ConditionBrowseBranchName":"Diseases and Abnormalities at or Before Birth"
              },{
                "ConditionBrowseBranchAbbrev":"BC20",
                "ConditionBrowseBranchName":"Immune System Diseases"
              },{
                "ConditionBrowseBranchAbbrev":"BC14",
                "ConditionBrowseBranchName":"Heart and Blood Diseases"
              },{
                "ConditionBrowseBranchAbbrev":"Rare",
                "ConditionBrowseBranchName":"Rare Diseases"
              }
            ]
          }
        }
      }
    }
  }
}